pp-238 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Platinum-resistant Ovarian Cancer (PROC), NSCLC / Clinical stage: Phase 1b/2/2 / Modality: Biologic - antibody-drug conjugate (ADC) with tubulysin payload / Mechanism & Target: NaPi2b-directed topoisomerase-I inhibitor ADC / Route & form: IV / Differentiation: Next-generation ADC with tubulysin; superior ORR vs benchmark
Manufacturer #39442
| Clinical-stage biotechnology company developing next-generation antibody-drug conjugates for oncology. Advances proprietary linker-payload platform targeting solid tumors with differentiated therapeutic profiles. Pipeline programs supported by a major global strategic partnership. |
None